Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Legacy Capital Wealth Partners LLC

Legacy Capital Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,885 shares of the medical research company’s stock after buying an additional 218 shares during the quarter. Legacy Capital Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,001,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in TMO. U.S. Capital Wealth Advisors LLC grew its position in Thermo Fisher Scientific by 2.1% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 8,606 shares of the medical research company’s stock worth $4,356,000 after buying an additional 175 shares during the last quarter. Valeo Financial Advisors LLC boosted its stake in Thermo Fisher Scientific by 6.7% in the 3rd quarter. Valeo Financial Advisors LLC now owns 3,399 shares of the medical research company’s stock worth $1,721,000 after purchasing an additional 214 shares during the period. Manning & Napier Group LLC boosted its stake in Thermo Fisher Scientific by 1.9% in the 3rd quarter. Manning & Napier Group LLC now owns 142,994 shares of the medical research company’s stock worth $72,379,000 after purchasing an additional 2,655 shares during the period. Linden Thomas Advisory Services LLC boosted its stake in Thermo Fisher Scientific by 8.8% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company’s stock worth $783,000 after purchasing an additional 125 shares during the period. Finally, Bfsg LLC boosted its stake in Thermo Fisher Scientific by 3.9% in the 3rd quarter. Bfsg LLC now owns 4,126 shares of the medical research company’s stock worth $2,088,000 after purchasing an additional 154 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,277 shares of company stock worth $28,513,384. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock traded up $1.87 during mid-day trading on Friday, hitting $573.60. The stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The firm has a market capitalization of $218.95 billion, a P/E ratio of 36.79, a P/E/G ratio of 2.42 and a beta of 0.80. The firm has a fifty day simple moving average of $573.60 and a 200 day simple moving average of $530.14.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TMO. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Royal Bank of Canada raised their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Finally, Barclays raised their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $606.76.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.